Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Breast Cancer
NCT07162519Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of romiplostim in Thrombocytopenia, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 2-week response rate (Platelet count >= 100x10^9/L). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07162519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162519.